Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

Study ID
NCT01272557

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

SoraDox

Trial Summary

This study is a prospective, randomized, open-label, multicenter phase IIB trial in order to determine time to progression of the combination therapy sorafenib plus doxorubicin against standard-of-care sorafenib in advanced HCC not amenable to non-systemic treatment.

More informations

Trial Starting Date

Dec 31,2010

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

170